Safety of Biologics Therapy

More about the book

This comprehensive title offers a state-of-the-art review of approved biologic therapies, covering mechanisms of action, indications for therapy, immunogenicity, and a detailed examination of adverse effects and safety across 13 chapters. By 2016, biologics are projected to represent half of the world's top 20 selling drugs, with sales expected to account for nearly half of the top 100 by 2018. Recombinant proteins lead the list of over 200 approved biotherapeutic agents, which include targeted antibodies, fusion proteins, receptors, cytokines, hormones, enzymes, blood-clotting proteins, vaccines, botulinum neurotoxins, and biosimilars. Aimed at clinicians, healthcare professionals, and researchers, this work addresses the full spectrum of safety issues related to approved biologic therapies. Understanding the risks and safety concerns of modern biologics is increasingly essential for those involved in their development, handling, prescribing, administration, and patient management. This book is invaluable for clinicians across various medical fields, nurses, pharmacists, researchers, and students in undergraduate and graduate programs in related disciplines and biomedical sciences.